Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein as Treatment for Gout Flare. Journal Abstract - Guideline Central

Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein as Treatment for Gout Flare.

Published: 2026 Apr

Authors

, , , ,

Abstract

A single-center, prospective, random, open-label study of acute gout patients treated with etanercept.

Keywords: etanercept, gout, recombinant human tumor necrosis factor receptor fusion protein

Source

International journal of rheumatic diseases

Publication Type

Journal Article

Language

English

PubMed ID

41949339

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.